AbbVie adds to data supporting Imbruvica in CLL and SLL

7 June 2016
2019_biotech_test_vial_discovery_big

US pharma major AbbVie (NYSE: ABBV) has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL).

The findings, which were presented at the 2016 American Society of Oncology (ASCO) Annual Meeting, include an analysis of outcomes from the RESONATE and RESONATE-2 trials, which showed Imbruvica was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy.

Other data includes first-ever follow-up data from the HELIOS trial, which showed that Imbruvica in combination with bendamustine and rituximab (BR) continued to demonstrate superiority over time versus placebo plus BR in relapsed/refractory CLL/SLL patients. Improvements in quality of response were also noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology